Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

CUE-101 Plus Pembrolizumab Yields 50% ORR in HPV+ HNSCC With Low PD-L1 Expression

July 16th 2025

In patients with HPV16-positive HNSCC, CUE-101 plus pembrolizumab generated 2 complete responses and a 12-month overall survival rate of 88%.

FDA Grants Orphan Drug Designation to SH-110 for Oral Suspension in Glioma

July 16th 2025

SH-110 received orphan drug designation from the FDA for the treatment of patients with glioma.

Sarilumab Plus Ipilimumab, Nivolumab, and Relatlimab Displays High Response Rate in Unresectable Melanoma

July 15th 2025

The combination of sarilumab, ipilimumab, nivolumab, and relatlimab displayed activity in patients with stage III or IV melanoma.

New Approaches Combat GVHD and Improve Transplantation Outcomes in Hematologic Malignancies

July 15th 2025

In an OncLive Peer Exchange filmed during EBMT, investigators discuss approaches to optimizing allo-HSCT and preventing GVHD in hematologic malignancies.

Regorafenib Plus Trifluridine/Tipiracil Shows Early Efficacy in Refractory Metastatic Colorectal Cancer

July 14th 2025

Regorafenib plus trifluridine/tipiracil was active in patients with pretreated metastatic colorectal cancer.

Dostarlimab Plus Chemo Prolongs Time to First, Second Subsequent Therapy Regardless of Age in Endometrial Cancer

July 11th 2025

After 3 years of follow-up, dostarlimab plus chemotherapy was effective and tolerable in patients aged 70 years or older with endometrial cancer.

Lisaftoclax Wins Chinese Approval in Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

July 11th 2025

The NMPA has approved lisaftoclax in adult patients with relapsed/refractory CLL/SLL.

FDA Grants Orphan Drug Designation to ADRX-0405 for Gastric Cancer

July 11th 2025

ADRX-0405 has received orphan drug designation from the FDA for the treatment of patients with gastric cancer.

Obe-Cel Is Effective Irrespective of Age in Relapsed/Refractory B-ALL

July 11th 2025

Obecabtagene autoleucel proved active and safe as treatment for patients with relapsed/refractory B-cell acute lymphoblastic leukemia regardless of age.

FDA Releases CRLs for Previous Drug and Biologic Product Applications

July 10th 2025

The FDA has published a collection of complete response letters that were seeking the approval of drugs or biologic products between 2020 and 2024.

Fixed-Duration Ibrutinib Plus Venetoclax Demonstrates Long-Term Efficacy in Untreated CLL/SLL

July 9th 2025

Fixed-duration ibrutinib plus venetoclax was effective with nearly 70 months of follow-up in patients with untreated CLL/SLL.

Expert Investigators Highlight Cross-Cancer Updates for Fellows From the 2025 AACR Annual Meeting

July 1st 2025

Experts in the fields of lung, head and neck, HER2+ breast, and hematologic cancers discuss notable updates for fellows from the 2025 AACR Annual Meeting.

Dr Halmos on Differentiating Neuroendocrine Tumors From Neuroendocrine Carcinomas

June 27th 2025

Balazs Halmos, MD, discusses the differences in presentation and available treatments between neuroendocrine tumors and neuroendocrine carcinomas.

Obrixtamig Leverages DLL3 Targeting to Offer a Potential Treatment Option in Extrapulmonary Neuroendocrine Carcinoma

June 27th 2025

Balazs Halmos, MD, discusses the DLL3-targeted BiTE obrixtamig for the treatment of patients with extrapulmonary neuroendocrine carcinoma.

Quizartinib Plus Chemotherapy Shows Strong Activity in FLT3-ITD–Positive, NPM1-Mutated AML

June 26th 2025

FLT3-ITD positivity plus mutations in NPM1 and epigenetic regulatory genes led to heightened efficacy of quizartinib plus chemotherapy in newly diagnosed AML.

NCCN Guidelines Now Recommend Taletrectinib for ROS1+ NSCLC

June 25th 2025

The NCCN Clinical Practice Guidelines in Oncology for NSCLC recommend taletrectinib for the treatment of patients with advanced ROS1-positive NSCLC.

FDA Grants Priority Review to Revumenib for Relapsed/Refractory NPM1-Mutant AML

June 25th 2025

Revumenib’s sNDA has received priority review from the FDA for patients with relapsed or refractory NPM1-mutant acute myeloid leukemia.

Additional Treatment Options Underscore the Need for Collaboration and Mutational Testing in GIST

June 24th 2025

Robin Jones MD, MBBS, MRCP, discusses the treatment landscape of GIST and how patients can be effectively treated in the community.

Real-World Data Help to Inform Treatment Selection in Metastatic Urothelial Carcinoma

June 23rd 2025

Amit Mehta, MD, discusses the landscape of metastatic urothelial carcinoma, including data updates as well as treatment selection and safety considerations.

Oncology Fellowship Often Fails to Include Training in Gender Equity Issues

June 23rd 2025

Ana Velázquez Mañana, MD, MSc, discusses survey findings that revealed gender equity training for oncology fellows is often lacking.